Therapeutic Monocytes for Prevention of Suicidal Ideation

This forum is to discuss general things concerning TSOI.
Post Reply
User avatar
TimGDixon
Posts: 938
Joined: Fri Jun 26, 2020 4:36 am

Therapeutic Monocytes for Prevention of Suicidal Ideation

Post by TimGDixon »

Abstract:
The invention discloses compositions of matter, protocols, and therapeutic means for treatment of suicidal ideations and/or suppression of suicidal attempts. In one embodiment the invention provides the use of umbilical cord derived monocytes as a means of treatment. In another embodiment, monocytes are de-differentiated from adult monocytes using reprogramming means to create monocyte capable of producing anti-inflammatory as well as regenerative properties useful in reducing suicidal ideations and/or attempts.

As usual i like to share with you at least some of the background on yesterdays new patent titled "Therapeutic Monocytes for Prevention of Suicidal Ideation".

Example 1: Suppression of Inflammation Induced Memory Dysfunction by Cord Blood Derived Monocytes
The lipopolysaccharide administration model was used to replicate neuroinflammation associated with suicidal behavior. Female BALB/c mice were treated with control, daily lipopolysaccharide treatment (10 ng/mouse0, and some with cord blood derived monocytes. Cord blood derived monocytes were extracted by ficoll separation of cord blood mononuclear cells and 4-hour incubation on T175 plastic flasks. Non-adherent cells were washed off by rinsing with phosphate buffered saline and adherent cells where subsequently dissociated using trypsin and placed into another flask. Cord blood monocytes where cultured for 24 hours with 1 IU of oxytocin per million cells in complete DMEM media with 10% fetal calf serum. Cells were dissociated with trypsin, washed in phosphate buffered saline and administered intravenously vial tail vein at a concentration of 500,000 per mouse on days 0, 3, and 6.

To assess memory function, water filled basin which was 120 cm in diameter was broken into 4 quadrants. 10 cm diameter platform placed 1 cm below water. Mice were forced to swim to find the hidden platform, starting from all four different quadrants, each day for a total of 7 days. As seen below, mice receiving umbilical cord monocytes resisted the pathological effects of lipopolysaccharide treatment.
mono-ex1.jpg
mono-ex1.jpg (134.1 KiB) Viewed 176 times

Example 2: Suppression of LPS Induced Plasma Interleukin-6 by Cord Blood Derived Monocytes
The lipopolysaccharide administration model was used to replicate neuroinflammation associated with suicidal behavior. Female BALB/c mice were treated with control, daily lipopolysaccharide treatment (10 ng/mouse0, and some with cord blood derived monocytes. Cord blood derived monocytes were extracted by ficoll separation of cord blood mononuclear cells and 4-hour incubation on T175 plastic flasks. Non-adherent cells were washed off by rinsing with phosphate buffered saline and adherent cells where subsequently dissociated using trypsin and placed into another flask. Cord blood monocytes where cultured for 24 hours with 1 IU of oxytocin per million cells in complete DMEM media with 10% fetal calf serum. Cells were dissociated with trypsin, washed in phosphate buffered saline and administered intravenously vial tail vein at a concentration of 500,000 per mouse on days 0, 3, and 6.

To assess interleukin 6 levels in plasma, mice were sacrificed at the indicated timepoints and cytokine was assayed by ELISA.

mono-ex2.jpg
mono-ex2.jpg (117.04 KiB) Viewed 176 times
Post Reply